IFNG gene signature overexpression	Lymphoma	IFNG gene signature overexpression	Lymphoma	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3
IFNG gene signature overexpression	Head and Neck Cancer	IFNG gene signature overexpression	Head and Neck Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3
IFNG gene signature overexpression	Cervical Cancer	IFNG gene signature overexpression	Cervical Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3
IFNG gene signature overexpression	Urothelial Cancer	IFNG gene signature overexpression	Urothelial Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3
IFNG gene signature overexpression	Melanoma	IFNG gene signature overexpression	Melanoma	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3
IFNG gene signature overexpression	Pancreatic Cancer	IFNG gene signature overexpression	Pancreatic Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3
IFNG gene signature overexpression	Renal Cell Carcinoma	IFNG gene signature overexpression	Renal Cell Carcinoma	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3
PD-L1 expression	Bladder Cancer	PD-L1 expression	Bladder Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3	nivolumab + BMS-986205 Sensitive: C3 – Early Trials nivolumab + BMS-986205 Sensitive : C3
KRAS mutation	Lung Adenocarcinoma	KRAS mutation	Lung Adenocarcinoma	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3
PD-L1 expression	Renal Cell Carcinoma	PD-L1 expression	Renal Cell Carcinoma	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3
IDO1 positive	Melanoma	IDO1 positive	Melanoma	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3
BRAF mutation	Melanoma	BRAF mutation	Melanoma	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3
PD-L1 expression	Melanoma	PD-L1 expression	Melanoma	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3	pembrolizumab + INCB024360 Sensitive: C3 – Early Trials pembrolizumab + INCB024360 Sensitive : C3

IDO1 inhibitor

IDO1 inhibitor

Associations(14)

Associations
(14)